Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571131 | 1.00 | CTSS (0.43) | CTSSCTSKKDM4DS1PR3TRPA1 | |
| SCHEMBL30765251 | 0.89 | CTSS (0.43) | CTSSCTSKS1PR3TRPA1ACE | |
| SCHEMBL3762203 | 0.89 | CTSS (0.43) | CTSSCTSKS1PR3TRPA1ACE | |
| SCHEMBL1115364 | 0.88 | KDM4D (0.41) | CTSSCTSKKDM4DS1PR3TRPA1 | |
| SCHEMBL29483428 | 0.88 | KDM4D (0.41) | CTSSCTSKKDM4DS1PR3TRPA1 | |
| SCHEMBL2898640 | 0.88 | CTSS (0.41) | CTSSCTSKS1PR3TRPA1ACE | |
| SCHEMBL15670482 | 0.88 | KDM4D (0.41) | CTSSCTSKKDM4DS1PR3TRPA1 | |
| SCHEMBL2833785 | 0.87 | S1PR3 (0.50) | CTSSCTSKKDM4DS1PR3TRPA1 | |
| SCHEMBL27189327 | 0.87 | CTSS (0.40) | CTSSCTSKS1PR3TRPA1ACE | |
| SCHEMBL23413921 | 0.86 | TRPA1 (0.45) | CTSSCTSKS1PR3TRPA1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4148050-B1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2024-12-18 | — | — | EP | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-115884968-B | Novel acid secretion inhibitor and use thereof | 日东制药株式会社 | 2024-06-21 | — | — | CN | disclosed |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230373954-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-23 | — | — | US | disclosed |
| US-11767311-B2 | Acid secretion inhibitor and use thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-09-26 | — | — | US | disclosed |
| US-20230192650-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| WO-2009137657-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1791837-B1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1791837-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029862-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767311-B2 | Acid secretion inhibitor and use thereof | SLC10A2, SLC10A1, ASIC1 | CTSS 1286/4885CTSK 1243/4885KDM4D 4473/4885 |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | CTSS 431/4885CTSK 249/4885KDM4D 3433/4885 |
| US-20230373954-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | SLC10A2, SLC10A1, ASIC1 | CTSS 1152/4885CTSK 1061/4885KDM4D 4493/4885 |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | RET, BRAF, ROR1 | CTSS 4415/4885CTSK 3558/4885KDM4D 1091/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | CTSS 97/4885CTSK 322/4885KDM4D 2483/4885 |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | IAPP, APP, BACE1 | CTSS 589/4885CTSK 706/4885KDM4D 4624/4885 |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | CTSS 3908/4885CTSK 2891/4885KDM4D 4397/4885 |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | CTSS 431/4885CTSK 249/4885KDM4D 3433/4885 |
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CTSS 1158/4885CTSK 1629/4885KDM4D 834/4885 |
| US-20230192650-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | SLC10A2, SLC10A1, ASIC1 | CTSS 1152/4885CTSK 1061/4885KDM4D 4493/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | CTSS 431/4885CTSK 249/4885KDM4D 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.